Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases.
The last earnings update was 72 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Anavex Life Sciences. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
Anavex Life Sciences's
is considered below, and whether this is a fair price.
Price based on past earnings
Anavex Life Sciences's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Anavex Life Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Anavex Life Sciences
expected to grow at an
Unable to compare Anavex Life Sciences's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Anavex Life Sciences's earnings growth to the Germany market average as no estimate data is available.
Unable to compare Anavex Life Sciences's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if Anavex Life Sciences is high growth as no earnings estimate data is available.
Unable to determine if Anavex Life Sciences is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Anavex Life Sciences's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
Anavex Life Sciences
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Anavex Life Sciences's finances.
The net worth of a company is the difference between its assets and liabilities.
Anavex Life Sciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Anavex Life Sciences has no long term commitments.
This treemap shows a more detailed breakdown of
Anavex Life Sciences's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Anavex Life Sciences has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Christopher U. Missling, also known as the Chris, MS, Ph.D., MBA. has been the Chief Executive Officer and President at Anavex Life Sciences Corp. since July 05, 2013 and served as its Chief Financial Officer, Secretary and Treasurer since July 05, 2013. Dr. Missling serves as the Chief Financial Officer of SEE ALGAE Technology GmbH. He serves as a Secretary of Anavex Life Sciences Corp. Dr. Missling is a Partner of New York based investment bank Brimberg & Co and has over 15 years of finance experience. He is an Investment Banker at Deutsche Bank, serving companies across various industries. Dr. Missling served as Senior Vice President of Finance, Treasurer and Secretary of Asahi Kasei Pharma America Corporation (Previously known as Artisan Pharma, Inc.) Dr. Missling has extensive financial management, operational and strategic experience in the biotechnology and pharmaceutical industries. Dr. Missling served as the Chief Financial Officer of ImmunoGen Inc., from October 25, 2004 to January 2005 and also served as its Vice President of Finance and Treasurer. He also served as the Chief Financial Officer, Senior Vice President of Finance, Treasurer and Secretary of Curis, Inc. from August 2002 to November 2003 and Senior Vice President of Strategic Analysis and Planning from November 2003. Dr. Missling served as Chief Financial Officer of Axaron Bioscience AG from November 2001 to August 2002. From October 2001 to January 2002, Dr. Missling served as Head of Financial Planning of Aventis SA, with responsibility for financial modeling and determining investment valuations. From July 1997 to December 1999, he served as Head of Financial Planning at Hoechst AG. Dr. Missling was with Deutsche Bank in corporate finance and investment banking serving pharmaceutical, biotech and diagnostic companies. He served as an Analyst in the pharmaceutical /healthcare investment banking group of Deutsche Morgan Grenfell. Dr. Missling has been Chairman at Anavex Life Sciences Corp. since July 5, 2013. Dr. Missling received his MBA from the Kellogg Graduate School of Management at WHU and Northwestern University, with a focus on partnership valuations in the Biotechnology and Pharmaceutical industries and his Ph.D., in Chemistry, summa cum laude and MSc from Ludwig-Maximilians-University in Munich.
Chris's compensation has been consistent with company performance over the past year.
Chris's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
Anavex Life Sciences
management team in years:
The tenure for the Anavex Life Sciences management team is about average.
Principal Financial Officer & Treasurer
Senior Vice President of Operations
Senior Vice President of Regulatory Affairs
Chief Medical Officer
Board of Directors Tenure
Average tenure and age of the
Anavex Life Sciences
board of directors in years:
The tenure for the Anavex Life Sciences board of directors is about average.
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company’s lead drug candidate is ANAVEX 2-73, which has completed Phase 2a clinical trial for Alzheimer’s disease; and preclinical clinical trials to treat Parkinson’s disease, Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis. It is also developing ANAVEX 3-71 to treat Alzheimer’s disease; ANAVEX 1-41, a sigma-1 agonist; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was founded in 2006 and is based in New York, New York.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.